openPR Logo
Press release

Mitochondrial Myopathy Diagnosis & Treatment Market to Reach USD 33.6 Million by 2020, Registering 9.82 % of CAGR; Asserts MRFR

04-03-2019 08:16 AM CET | Health & Medicine

Press release from: Market Research Future

Mitochondrial Myopathy Diagnosis & Treatment Market

Mitochondrial Myopathy Diagnosis & Treatment Market

The Report of Global Mitochondrial Myopathy Diagnosis & Treatment Market by Market Research Future Covers the Information like Global New-Born Screening Market Growth, Prominent Players, Upcoming Trends, Business Analysis, chapter-wise Description followed by various user perceptions.

Market Overview:

Many of the genetic defects that cause this disease have been identified; animal models are created and used to knowledge them. Although MM is relatively rare & a genetic defect, some of its risk factors like heart problems, seizures, and diabetes are fairly prevailing in the general population. Therefore, adopting a healthy lifestyle certainly does help to ease the conditions.

Get Free Sample Copy at https://www.marketresearchfuture.com/sample_request/3950

Considering all these factors, the market for mitochondrial myopathy diagnosis & treatment is expected to reach $ 33.6 million by the end of 2020, this market is projected to growing at a CAGR of ~ 9.82 % during 2017-2020. Mitochondrial Myopathy (MM) disease refers to the major muscular problems, caused by changes or mutations in genes. Hence, understanding the genetic defects that cause MM opens up the possibility of developing treatments for this disease. There have been many novel medicines & therapies developed to treat symptoms of MM. Unfortunately, these treatable symptoms of Mitochondrial Myopathy are often the most life-threatening complications.

Researches to fully understand and treat the diseases have achieved significant progresses. In one of the unique progress is experimenting with infusing donor stem cells into patients with MNGIE disease, is expected to restore normal metabolic conditions and halt damage to the mitochondria. Many such researches undergoing simultaneously, define the growth the Mitochondrial Myopathy Diagnosis & Treatment market perceives today.

Acknowledging the exponential growth the market perceives currently and gauging the potential the market holds to grow in the future; Market Research Future (MRFR), in its recently published market forecast asserts that the global Mitochondrial Myopathy will grow to USD 33.6 million by 2020, registering a striking ~ 9.82 % CAGR throughout the forecast period (2017 – 2020).

In addition to the prevalence of MM disease with the prevailing chronic diseases like diabetes and heart problems, other factors contributing the market growth include increasing population & urbanization along with the growing awareness about the treatments of MM, across the world. Improving economic conditions that enable access to the quality life & to the improved healthcare worldwide are providing impetus to the market growth.

Key Players:

Centogene AG, GeneDx, Ixchel Pharma, Khondrion BV, Mitobridge, NeuroVive Pharmaceutical AB, Reata Pharmaceuticals Inc., and Stealth Biotherapeutics.

Industry/Innovation/ Related News:

April 18, 2018 – NeuroVive Pharmaceutical AB (Sweden), one of the leading global companies in mitochondrial medicine announced that its investigative compound NV556 has proven to be having therapeutic potential for the treatment of mitochondrial myopathy.

Recently the company had conducted a preclinical study in collaboration with researchers at KarolinskaInstutet (Sweden) one of the world's leading medical universities. The Investigative Compound NV556, demonstrating the d promising results, was proven to be a breakthrough treatment for the mitochondrial myopathy in animals compared to placebo.

October 07, 2017 – Stealth BioTherapeutics (US), a leading clinical-stage biopharmaceutical company announced that FDA has granted orphan drug status to its elamipretide (Bendavia), an investigational medicine for the treatment of PMM (primary mitochondrial myopathy).

Mitochondrial Myopathy Diagnosis & Treatment Market   - Competitive Analysis

The global market of Mitochondrial Myopathy Diagnosis & Treatment appears to be fiercely competitive with the several well-established and small players operating in the market. These players incorporate collaboration, acquisition, expansion, strategic partnership, & technology launch. Top players are investing heavily in R&D and clinical trials to develop effective drugs.

Mitochondrial Myopathy Diagnosis & Treatment Market - Segmentations

Global Mitochondrial Myopathy Diagnosis & Treatment Market is segmented in to 4 Key dynamics for an easy grasp and enhanced understanding.

By Types: Comprises - MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, &Stroke-Like Episodes), PEO (Progressive External Ophthalmoplegia), MERRF (Myoclonic Epilepsy With Ragged Red Fibres), MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy Syndrome), KSS (Kearns–Sayre syndrome), MDS (Mitochondrial DNA Depletion Syndrome), NARP (Retinitis Pigmentosa), Pearson Syndrome, Neuropathy, Leigh Syndrome, and Ataxia.

By Diagnostic Tests:Genetic Tests, Muscle Biopsy and Biochemical Test among others.

By Therapies:Supportive Therapy and Targeted Therapy among others.

By Regions:  Europe, North America, APAC and Rest of the World.

Mitochondrial Myopathy Diagnosis & Treatment Market - Regional Analysis

Globally North America leads the global market of Mitochondrial Myopathy Diagnosis & Treatment with the largest market share. The North American market is expected to grow to USD 116.7 million by 2020 at a CAGR of 19.39% during 2016 to 2020. This growth attributes to the favourable reimbursement scenario and greater expenditure on healthcare. The rapid uptake of new technologies in the US is also an important driver for the regional market growth.

Europe is expected to be the second-largest market for Mitochondrial Myopathy Diagnosis & Treatment which is expected to grow at a considerable CAGR.  Improving economy in the region is expected to foster the regional market growth. 

While Asia Pacific market for the Mitochondrial Myopathy Diagnosis & Treatment is expected to perceive the growth of USD 4.4 million by 2020 at a CAGR of 9.94% during 2016 to 2020. The market growth will be led by China and India owing to the huge population and the availability of low-cost drugs for the treatment. Moreover, the fastest growing healthcare sector coupled with the large unmet needs over the forecast period will provide impetus to the market growth. Vietnam, Thailand, and Malaysia among the other South East Asian countries are projected to contribute significantly to the regional market growth. Besides the growing penetration of healthcare insurance is expected to drive the Mitochondrial Myopathy Diagnosis & Treatment market in the in the Asia Pacific region.

Get Full Report at https://www.marketresearchfuture.com/reports/mitochondrial-myopathy-diagnosis-treatment-market-3950

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Mitochondrial Myopathy Diagnosis & Treatment Market to Reach USD 33.6 Million by 2020, Registering 9.82 % of CAGR; Asserts MRFR here

News-ID: 1684832 • Views:

More Releases from Market Research Future

Global Small Boat Industry Sees Growing Demand Amid Rising Recreational Boating and Coastal Activities
Global Small Boat Industry Sees Growing Demand Amid Rising Recreational Boating …
As per the latest analysis by Market Research Future, the Small Boats Market Size was estimated at 17.12 (USD Billion) in 2024. The Small Boats Market Industry is expected to grow from 17.88 (USD Billion) in 2025 to 26.41 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.43% during the forecast period (2025 - 2034). The global small boat industry is witnessing significant growth, driven
Automotive Trim Market Attaining USD 193.22 Billion till 2034 | Innovations Redefine Vehicle Aesthetics and Functionality
Automotive Trim Market Attaining USD 193.22 Billion till 2034 | Innovations Rede …
As per the latest analysis by Market Research Future, the Automotive Trim Market Size was estimated at 140.30 (USD Billion) in 2024. The Automotive Trim Market Industry is expected to grow from 144.87 (USD Billion) in 2025 to 193.22 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.25% during the forecast period (2025 - 2034). The automotive industry is witnessing a significant transformation in vehicle
Leading Automotive Technology Firms Expand Fuel Level Sensor Solutions for Next-Generation Vehicles | Robert Bosch Gmbh, Technoton
Leading Automotive Technology Firms Expand Fuel Level Sensor Solutions for Next- …
As per the latest analysis by Market Research Future, Automotive Fuel Level Sensor Market Size was valued at USD 5,788.04 million in 2024. The Automotive Fuel Level Sensor market industry is projected to grow from USD 6,008.32 million in 2025 to USD 9,201.90 million by 2035, exhibiting a compound annual growth rate (CAGR) of 4.35% during the forecast period (2024 - 2035). With the global automotive industry focused on precision,
Valet Parking Technology Gains Momentum as Urban Mobility and Smart Infrastructure Evolve | Market Growth with 15.62% CAGR
Valet Parking Technology Gains Momentum as Urban Mobility and Smart Infrastructu …
As per the latest analysis by Market Research Future, the Valet Parking Technology Market Size was estimated at 1.41 (USD Billion) in 2024. The Valet Parking Technology Market Industry is expected to grow from 1.63 (USD Billion) in 2025 to 6.01 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 15.62% during the forecast period (2025 - 2034). Valet parking technology is emerging as a transformative

All 5 Releases


More Releases for Mitochondrial

Mitochondrial Myopathies Market Trends,Developments, and Growth Opportunities
Mitochondrial myopathies are a group of rare, genetically inherited neuromuscular disorders that result from dysfunction in the mitochondria-the powerhouses of the cell. These conditions often manifest as muscle weakness, fatigue, exercise intolerance, and in severe cases, multi-system complications affecting the heart, brain, and other organs. With increasing recognition of rare diseases, advancements in genetic diagnostics, and novel therapeutic development, the Mitochondrial Myopathies market is experiencing significant growth potential. Download Full PDF
Primary Mitochondrial Myopathies Pipeline Insight 2025: Novel Mitochondrial Modu …
The therapeutic landscape for Primary Mitochondrial Myopathies (PMM) is evolving rapidly, with novel approaches emerging to address the debilitating effects of impaired mitochondrial energy metabolism. PMM, a rare and heterogeneous group of disorders, currently lacks disease-modifying treatments, with care largely limited to symptom management, supportive measures, and nutritional supplements. This ongoing unmet need is fueling innovation across multiple therapeutic modalities. DelveInsight's "Primary Mitochondrial Myopathies - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/primary-mitochondrial-myopathies-pmm-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" highlights an
Brain Recovery After Concussion: Neurofeedback & Hyperbaric Oxygen for Mitochond …
San Diego, CA - August 06, 2025 - An increasing amount of neuroscience research shows that the real damage of a concussion goes far beyond just a "bump on the head." At the cellular level, concussions can cause mitochondrial problems, leading to a chain reaction of metabolic, inflammatory, and cognitive issues in the brain. New therapies like neurofeedback and hyperbaric oxygen therapy (HBOT) are now demonstrating promising results in helping
Mitochondrial Complex Activity Assay Kits Market Growth by 2034
The global mitochondrial complex activity assay kits market is poised for a major leap, projected to reach USD 567 million by 2034 from an estimated USD 275 million in 2024, growing at a CAGR of 7.4%. This growth is fueled by increased demand for mitochondrial health assessment in drug discovery, cancer research, and chronic disease diagnostics. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/67131 Key Highlights: • Market Size (2024): USD 275 million • Forecasted
Advanced Mitochondrial Formula Reviews: The Real Fact About Advanced Mitochondri …
Advanced Mitochondrial Formula Reviews: The Real Fact About Advanced Mitochondrial Formula It started with small things. Skipping your morning jog because you "didn't sleep well." Grabbing an extra cup of coffee by mid-afternoon just to make it through another Zoom meeting. Forgetting simple names or misplacing your phone more often. Maybe you've brushed it off as stress, getting older, or just the pace of modern life but deep down, you know
Primary Mitochondrial Myopathies (PMM) Pipeline: Advancing Therapies Targeting M …
The therapeutic landscape for Primary Mitochondrial Myopathies (PMM) is rapidly progressing, driven by the urgent need to address the complex and heterogeneous nature of these rare genetic disorders characterized by mitochondrial dysfunction and impaired energy production. Despite limited approved treatment options, ongoing research focuses on novel approaches to improve mitochondrial function, enhance cellular energy metabolism, and alleviate symptoms. Leading biotech and pharmaceutical companies, including Stealth BioTherapeutics, Omeicos Therapeutics GmbH, and